Fibrin sealant - Angiotech Pharmaceuticals
Alternative Names: Hemaseel HMNLatest Information Update: 12 Jan 2022
At a glance
- Originator Haemacure Corporation
- Developer Angiotech Pharmaceuticals
- Class Antihaemorrhagics; Blood coagulation factors; Blood proteins; Serine endopeptidases
- Mechanism of Action Blood coagulation factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Suspended Burns; Haemorrhage; Post-surgical adhesions; Wounds
Most Recent Events
- 29 Mar 2012 Suspended - Phase-III for Haemorrhage in USA (Topical)
- 29 Mar 2012 Suspended - Phase-III for Wounds in USA (Topical)
- 29 Mar 2012 Suspended - Preclinical for Burns in USA (Topical)